Efficacy of Osimertinib in NSCLC Harboring Uncommon EGFR L861Q and Concurrent Mutations: Case Report and Literature Review

Overview of attention for article published in Frontiers in oncology, September 2021

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (65th percentile)
High Attention Score compared to outputs of the same age and source (89th percentile)

So far, Altmetric has seen 9 X posts from 8 X users, with an upper bound of 25,179 followers.

Efficacy of Osimertinib in NSCLC Harboring Uncommon EGFR L861Q and Concurrent Mutations: Case Report and Literature ... https://t.co/uLhc9sz8nR

RT @FrontOncology: New research: Efficacy of Osimertinib in NSCLC Harboring Uncommon EGFR L861Q and Concurrent Mutations: Case Report and L…

RT @FrontOncology: New research: Efficacy of Osimertinib in NSCLC Harboring Uncommon EGFR L861Q and Concurrent Mutations: Case Report and L…

RT @FrontOncology: New research: Efficacy of Osimertinib in NSCLC Harboring Uncommon EGFR L861Q and Concurrent Mutations: Case Report and L…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 5 additional X posts.